



09/10-02

PHA 4 .2 (2891/3)
PATENTOCT 16 2002
RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
TECH CENTER 2890
OCT 16 2002
09/10-02

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of P. Isakson et al.

Art Unit 1627

Serial No. 10/038,080

Filed January 3, 2002

Confirmation No. 7358

For TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED DISORDERS
WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A
LEUKOTRIENE B₄ RECEPTOR ANTAGONIST

Examiner Friend

September 9, 2002

AMENDMENT BTO THE ASSISTANT COMMISSIONER FOR PATENTS,
Washington, D.C. 20231

SIR:

In response to the Office action mailed August 9, 2002,
please enter the following amendments:**IN THE CLAIMS:****Please replace Claim 2 with the following:**

SJ

B

2. (twice amended) A combination comprising a therapeutically-effective amount of a leukotriene B₄ receptor antagonist and a cyclooxygenase-2 inhibitor selected from Taisho NS-398 (Methanesulfonamide, N-[2-(cyclohexyloxy)-4-nitrophenyl]), meloxicam (2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide), flosulide (Methanesulfonamide, -[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]), Merck MK-966 (2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl), Merck L-752,860 and compounds of Formula I

